Quantitative Investment Management LLC Purchases 6,152 Shares of Natera, Inc. $NTRA

Quantitative Investment Management LLC raised its position in Natera, Inc. (NASDAQ:NTRA) by 49.2% during the third quarter, Holdings Channel.com reports. The institutional investor owned 18,662 shares of the medical research company’s stock after purchasing an additional 6,152 shares during the quarter. Quantitative Investment Management LLC’s holdings in Natera were worth $3,004,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Sound Income Strategies LLC increased its holdings in shares of Natera by 95.7% during the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after buying an additional 110 shares in the last quarter. Quent Capital LLC acquired a new position in shares of Natera in the 3rd quarter worth approximately $46,000. Hilltop National Bank boosted its holdings in shares of Natera by 59.8% in the 3rd quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock worth $50,000 after acquiring an additional 116 shares in the last quarter. N.E.W. Advisory Services LLC grew its position in Natera by 256.8% during the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock worth $53,000 after acquiring an additional 226 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in Natera by 23.1% during the 3rd quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock valued at $69,000 after purchasing an additional 81 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced the commercial launch of its Zenith™ Genomics rare‑disease diagnostic product, marking a new commercial offering that could expand the company’s addressable market for clinical whole‑genome testing. Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis
• Positive Sentiment: MyOme debuted the Zenith™ portfolio with Natera and launched long‑read methylation analysis at ACMG 2026 — a technology/commercial collaboration that could broaden Natera’s diagnostic capabilities (epigenetic and long‑read WGS) and improve clinical utility over time. MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
• Positive Sentiment: Market reaction in the space: competing specialist GeneDx reported a share drop after Natera’s launch, suggesting investors see the new product as competitive and potentially share‑grabbing in the rare‑disease testing market. This is an indirect validation of the commercial opportunity. GeneDx stock falls as Natera launches competing rare disease test
• Neutral Sentiment: Natera presented at the Leerink Global Healthcare Conference (transcript available). The presentation provides management commentary on product adoption, reimbursement and growth drivers — useful for modeling but not an immediate market catalyst on its own. Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Insider selling: CEO Steven Chapman sold ~5,623 shares and other senior insiders (CFO Michael Brophy, John Fesko, Solomon Moshkevich) also sold shares on the same date. Multiple concurrent insider sales are weighing on sentiment and likely contributed to today’s downward pressure. SEC Form 4 — CEO Sale

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 17,806 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total transaction of $4,179,780.44. Following the completion of the sale, the insider directly owned 177,591 shares of the company’s stock, valued at approximately $41,687,711.34. The trade was a 9.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 23,205 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total transaction of $5,447,141.70. Following the transaction, the insider owned 144,992 shares in the company, valued at approximately $34,035,422.08. The trade was a 13.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 318,222 shares of company stock worth $74,068,068 in the last ninety days. 5.63% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Wells Fargo & Company lifted their price objective on Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Morgan Stanley decreased their target price on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Barclays raised their target price on Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. BTIG Research lifted their price target on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a report on Friday, December 5th. Finally, Stephens upped their price target on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $253.47.

Natera Stock Performance

NASDAQ:NTRA opened at $190.31 on Friday. The company has a market cap of $26.97 billion, a price-to-earnings ratio of -124.39 and a beta of 1.65. The stock’s fifty day moving average price is $220.54 and its two-hundred day moving average price is $205.96. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.During the same period last year, the firm earned ($0.41) EPS. On average, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.